Gerald L. Ray & Associates’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$37M Sell
253,919
-3,180
-1% -$433K 4.62% 2
2017
Q2
$33.4M Buy
257,099
+971
+0.4% +$119K 4.31% 2
2017
Q1
$31.9M Sell
256,128
-1,991
-0.8% -$238K 4.36% 2
2016
Q4
$29.9M Sell
258,119
-586
-0.2% -$65.3K 4.33% 2
2016
Q3
$27M Buy
258,705
+5,603
+2% +$606K 4.06% 2
2016
Q2
$25M Sell
253,102
-2,152
-0.8% -$223K 3.99% 2
2016
Q1
$25.5M Buy
255,254
+1,923
+0.8% +$198K 4.14% 2
2015
Q4
$30.3M Sell
253,331
-2,559
-1% -$296K 4.79% 3
2015
Q3
$27.7M Sell
255,890
-1,990
-0.8% -$247K 4.62% 3
2015
Q2
$29.8M Sell
257,880
-3,676
-1% -$420K 4.54% 3
2015
Q1
$30.2M Sell
261,556
-4,050
-2% -$484K 4.54% 2
2014
Q4
$29.7M Sell
265,606
-3,530
-1% -$372K 4.57% 2
2014
Q3
$25.5M Sell
269,136
-200
-0.1% -$18K 4.15% 2
2014
Q2
$23.1M Sell
269,336
-1,574
-0.6% -$120K 3.94% 2
2014
Q1
$18.9M Buy
270,910
+6,764
+3% +$536K 3.43% 3
2013
Q4
$22.3M Sell
264,146
-4,794
-2% -$379K 4.21% 1
2013
Q3
$20.7M Sell
268,940
-1,900
-0.7% -$133K 4.29% 2
2013
Q2
$15.8M Buy
+270,840
New +$16.3M 3.55% 2

Other funds holding CELG

Gerald L. Ray & Associates's CELG Position: Q3 2017 in Review

Gerald L. Ray & Associates reduced its Celgene Corp (CELG) stake by 1.2% in Q3 2017, selling an estimated $433K and leaving 253,919 shares worth $37M. The position accounts for 4.62% of the portfolio, ranked #2.

Gerald L. Ray & Associates first reported a position in CELG in Q2 2013 and has held it in 18 quarters since. 1,484 funds tracked by Wall St. Rank hold CELG as of Q3 2017.

  • Gerald L. Ray & Associates held 253,919 shares of Celgene Corp worth $37M as of Q3 2017.
  • Gerald L. Ray & Associates sold 3,180 Celgene Corp shares in Q3 2017, an estimated $433K.
  • Celgene Corp made up 4.62% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #2 holding.
  • Gerald L. Ray & Associates first reported a position in Celgene Corp in Q2 2013 and has held it in 18 quarters since.
  • 1,484 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.